Grants for Public Housing Authorities

This grant provides funding for collaborative research teams to develop and test strategies that address and reduce racial and ethnic disparities in substance use and addiction, prioritizing community-driven issues.

This grant provides funding for researchers to explore how Mycobacterium tuberculosis and HIV affect host cell death pathways, with the goal of developing new therapies to improve treatment outcomes for co-infected individuals.

This funding opportunity supports research centers focused on understanding how biological sex differences affect women's health, promoting interdisciplinary collaboration and workforce diversity in the scientific community.

This funding opportunity supports researchers exploring the biological mechanisms of bladder cancer to improve understanding and treatment of this prevalent disease.

This grant provides funding to early-career researchers in mental health to support innovative projects that advance the understanding and treatment of mental illnesses.

This funding opportunity supports research into the biology and mechanisms of bladder cancer, encouraging multidisciplinary teams to explore both normal bladder functions and cancer processes using clinical specimens.

This funding opportunity provides long-term financial support to experienced cancer researchers who are pursuing innovative and high-risk projects that could lead to significant advancements in cancer science.

This grant provides funding for innovative early-stage cancer research projects that could lead to significant advancements in diagnosis, treatment, and prevention, targeting a wide range of eligible organizations including universities, nonprofits, and small businesses.

This funding opportunity supports early-career clinical researchers in the U.S. to develop expertise in implementation science for substance use prevention and treatment through mentored clinical trials addressing the overdose crisis.

This funding opportunity supports early-career researchers in the U.S. to develop their skills in implementation science for effective substance use prevention and treatment, enabling them to lead clinical trials that address the opioid crisis.

This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.

This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

This grant provides funding to improve safety training programs for commercial fishermen in the United States, ensuring they receive effective education to reduce workplace injuries and enhance safety practices.

This grant provides funding for large-scale, collaborative research projects that explore complex questions related to aging, requiring a multidisciplinary team and integration of various components across institutions.

The "CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development" grant aims to fund the early-stage development of treatments to reduce the harmful health effects caused by exposure to toxic chemicals, which could be used in terrorist attacks or accidentally released from industrial sites, with the end goal of producing at least one well-characterized therapeutic candidate.

The "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required" grant aims to fund clinical trials that test the effectiveness and safety of new treatments for rare diseases, with the goal of increasing the number of approved treatments for these conditions.

This grant provides access to valuable biological samples and data for researchers studying common and serious health conditions, such as diabetes and kidney diseases, to support innovative research and development of new treatments.

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).Funding Opportunity Description Introduction The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), is transforming the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. This funding opportunity announcement (FOA) aims to promote innovative research to increase knowledge of understudied proteins associated with rare diseases. The submission of small research grant (R03) applications is encouraged from institutions and organizations proposing projects leading to a better understanding of eligible proteins listed below. Small research (R03) grants provide flexibility for initiating discrete, well-defined projects that realistically can be completed in one year and require only limited levels of funding. This program supports different types of projects including, but not limited to, the following: Pilot or feasibility studies; Small, self-contained research projects; Development of research methodology; and/or Development of assays to support compound screening projects; Development of human cell or animal based models. These awards will support generation of preliminary data and tools around eligible understudied protein(s) with the intent of elucidating the function of these proteins in the context of rare disease and obtaining sufficient preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. These grants are non-renewable. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Background The human genome has revealed a great deal about the human proteome, though significant portions of the genome remain understudied. Only a subset of expressed proteins demonstrates the requisite properties to serve as targets for the development of therapeutics. Many bona fide drug targets likely remain to be studied in the Druggable Proteome (DP), which can be defined as the fraction of proteins which have the ability to bind drug-like molecules. The term "drug-like" refers to the physical, biochemical, and pharmacological attributes of small molecule compounds that are generally recognized to be required for efficacious clinical drugs in humans. While the number of proteins in the DP is upwards of 4,500, the existing clinical pharmacopeia is represented by only a few hundred targets, leaving a huge swath of druggable biology unexploited. The expanded exploration of the relationship between the protein and the rare disease phenotype, or the development of a useful tool or reagent can accelerate research into a previously understudied protein. Many interesting and critical biological processes and potential therapeutic avenues remain unexplored because an initial catalyzing event (e.g., association with a biologic process or phenotype, creation of tools or reagents for the protein, etc.) has not yet occurred. The purpose of this FOA is to spark such catalyzing events through the support of small R03 awards to identify novel drug targets for the treatment of human disease, specifically rare disease Objectives and Scope The goal of this specific solicitation is to provide a needed opportunity for the collection of preliminary data around the role of understudied proteins associated with rare diseases. This FOA will provide funding to support research that will characterize new targets for treatment of human disease among the understudied proteins of the Druggable Proteome. These projects should be carried out in a short period of time with limited resources as defined by the funding mechanism. It has been recognized through workshops and publications that understudied proteins become illuminated when (1) there are tools to study the protein (e.g., tools that modulate protein activity) and/or (2) there is biochemical, cellular, or animal model evidence of disease/physiological relevance. This FOA was developed to address the need for expanded research and validation experiments on eligible understudied protein(s), with the intent of producing preliminary data to address the lack of biochemical, cellular, or animal model data associated with many understudied proteins. It is expected that the award will be used to obtain preliminary data and/or research resources for subsequent grant applications and/or drug discovery projects. The NIH supports research on a broad range of diseases that are defined as rare; that is diseases affecting fewer than 200,000 individuals in the United States (per the Rare Disease Act of 2002). Collectively, there are an estimated 7,000 rare diseases, which affect approximately 25-30 million people in the United States. Most are serious or life-threatening, with a disproportionate number of rare diseases affecting children. At this time, effective treatments are available for fewer than 5%. The IDG Program has linked over 6,000 proteins to rare diseases, with over 80% of these proteins considered extremely understudied. For the purposes of this FOA, eligible proteins are those that have an association with rare disease through data mining of the encyclopedia of rare disease annotations for precision medicine (eRAM) and Orphanet, are considered understudied (those proteins that lack small molecule binders and/or have limited biological characterization) and are within a protein family that is traditionally considered druggable.

This grant provides funding to researchers for planning clinical trials that improve cancer prevention, treatment, and care, addressing gaps in knowledge and feasibility to enhance study design and outcomes.

This grant provides funding to researchers planning clinical trials focused on cancer prevention and control, helping them address challenges and improve the design and feasibility of their studies.